Predictive Value of the Platelet indices in Diagnosis of Prostate Cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024884

Enrollment

Unknown

Registered

2019-08-02

Start date

2019-08-08

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Gold Standard:Pathological diagnosis of biopsy

Index test:PLT, MPV and PDW

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: prostate biopsy patients(pathological diagnosis positive and negative).

Exclusion criteria

Exclusion criteria: without other malignancies, family history of PCa, and long-term administration of drugs which effect on blood examination, blood pressure or related metabolism.

Design outcomes

Primary

Measure	Time frame
risk of prostate cancer;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactLiu Jiaxin

Zhejiang University

liujiaxin1124@zju.edu.cn+86 13386537776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026